SPRB

Spruce Biosciences, Inc. Common Stock

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Spruce Biosciences, Inc. Common Stock (SPRB) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 2.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -0.2
Rev Growth YoY -75.9%
Gross Margin N/M
Price Return 3M -25.3%
Price Return 12M 423.9%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 49.2
ROE -148.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-03 C+ (2.7) C- (2.1) C+ (2.6) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C- (2.1) C+ (2.6) C (2.4) C- (1.9) C (2.4)
2024-12-31 C+ (2.6) F (0.1) D- (1.0) D- (0.8) D (1.5) D (1.2)
2024-09-30 C+ (2.6) F (0.0) D+ (1.5) D- (0.8) D+ (1.5) D (1.3)
2024-06-30 C+ (2.6) D- (1.1) D+ (1.7) D- (0.8) D (1.5) D+ (1.6)
Page 1 of 2